Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Risedronate · 1 trial · 1 indication
change in spine bone density at 18 months measured by DXA 18 and 24 months
| Arm | Type | Description |
|---|---|---|
| Active Risedronate Placebo Teriparatide | ACTIVE_COMPARATOR | Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months |
| Active Risedronate Active Teriparatide | ACTIVE_COMPARATOR | Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months |
| Placebo Risedronate Active Teriparatide | ACTIVE_COMPARATOR | Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months |
| Name | Type | Description |
|---|---|---|
| Risedronate | DRUG | weekly risedronate |
| Teriparatide | DRUG | daily teriparatide |
| Placebo Teriparatide | DRUG | daily placebo of teriparatide |
| placebo Risedronate | DRUG | weekly placebo of Risedronic Acid |
Inclusion Criteria: 1. Males, ages 30-85 with osteoporosis. 2. Osteoporosis can be due to hypogonadism, past steroid use, or idiopathic. 3. Patients with hypogonadism can be included if their replacement dosage of testosterone has been stable for at least 18 months. 4. Bone mineral density must be ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |
Risedronate is used for the treatment of osteoporosis. It is a small molecule being developed by Bone Biologics Corp for this condition. In clinical trials, it has been studied in male patients with osteoporosis, with a completed Phase 3 trial evaluating its use in combination with parathyroid hormone.
Risedronate is a bisphosphonate that works by inhibiting bone resorption. It targets osteoclasts, the cells responsible for breaking down bone tissue, thereby helping to maintain bone density and reduce fracture risk in patients with osteoporosis.
Risedronate is being developed by Bone Biologics Corp, a company traded on the NASDAQ under the ticker symbol BBLG. The company is conducting clinical research on this drug for the treatment of osteoporosis.
Risedronate is in Phase 3 clinical development for osteoporosis. A Phase 3 trial has been completed, but the drug is still considered investigational and has not been approved by regulatory authorities. It remains in clinical development.
Risedronate has one completed Phase 3 clinical trial registered under NCT01611571, titled 'Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis.' This randomized, double-blind, active-controlled study enrolled 31 male patients aged 30 years and older with osteoporosis in the United States.
Risedronate is a specific bisphosphonate medication used for osteoporosis. It is not the same as other drugs in its class, such as alendronate or ibandronate, though they share a similar mechanism of action. Risedronate is being studied in combination with parathyroid hormone for male osteoporosis.